Brainstorm Cell Therapeutics (NASDAQ: BCLI) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Brainstorm Cell Therapeutics to related businesses based on the strength of its profitability, earnings, analyst recommendations, risk, dividends, institutional ownership and valuation.
This is a breakdown of current ratings and recommmendations for Brainstorm Cell Therapeutics and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Brainstorm Cell Therapeutics||0||0||1||0||3.00|
|Brainstorm Cell Therapeutics Competitors||572||2506||6735||133||2.65|
Valuation & Earnings
This table compares Brainstorm Cell Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Brainstorm Cell Therapeutics||N/A||-$4.98 million||-11.74|
|Brainstorm Cell Therapeutics Competitors||$217.40 million||-$39.40 million||-63.10|
Brainstorm Cell Therapeutics’ rivals have higher revenue, but lower earnings than Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Brainstorm Cell Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics’ rivals have a beta of 1.48, meaning that their average share price is 48% more volatile than the S&P 500.
Insider & Institutional Ownership
13.1% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 49.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 24.7% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Brainstorm Cell Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Brainstorm Cell Therapeutics||N/A||-76.45%||-59.84%|
|Brainstorm Cell Therapeutics Competitors||-4,594.30%||-35.39%||-43.41%|
Brainstorm Cell Therapeutics beats its rivals on 8 of the 13 factors compared.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.